68Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment

Pim J. van Leeuwen*†, Phillip Stricker*†, George Hruby‡§¶, Andrew Kneebone‡§¶, Francis Ting*†, Ben Thompson†, Quoc Nguyen†, Bao Ho** and Louise Emmett**††

*St Vincent’s Prostate Cancer Centre, St Vincent’s Clinic, Sydney, NSW, †Australian Prostate Cancer Research Centre – New South Wales, Garvan Institute of Medical Research/Kinghorn Cancer Centre, Sydney, NSW, ‡Radiation Oncology Department, Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, ¶University of Sydney, Sydney, NSW, *Northern Clinical School, University of Sydney, St Leonards, NSW, **Department of Diagnostic Imaging, St Vincent’s Public Hospital, Sydney, NSW, and ††University of New South Wales, Sydney, NSW, Australia

Objectives
To examine the detection rates of 68Ga-PSMA-positron emission tomography (PET)/computed tomography (CT) in patients with biochemical recurrence (BCR) after radical prostatectomy (RP), and also the impact on their management.

Materials and Methods
A total of 300 consecutive patients with prostate cancer (PCa) who underwent 68Ga-PSMA-PET/CT between February and July 2015 were prospectively included in the Prostate Cancer Imaging (ProCan-I) database. For the present analysis, we included patients with BCR (prostate-specific antigen [PSA] level ≥0.05 and <1.0 ng/mL) after RP, who were being considered for salvage radiation therapy (RT) according to the Faculty of Radiation Oncology Genito-Urinary Group (FROGG) guidelines. Two readers assessed each 68Ga-PSMA-PET/CT, and all positive lesions were assigned to an anatomical location. For each patient, the clinical and pathological features were recorded, their association with pathological 68Ga-PSMA uptake was investigated, and detection rates were determined according to PSA level.

Results
A total of 70 patients were included, and 53 positive 68Ga-PSMA lesions were detected in 38 (54%) patients. Among patients with PSA levels 0.05–0.09 ng/mL, 8% were definitely positive; the corresponding percentages for the other PSA ranges were as follows: PSA 0.1–0.19 ng/mL, 23%; PSA 0.2–0.29 ng/mL, 58%; PSA 0.3–0.49 ng/mL, 36%; and PSA 0.5–0.99 ng/mL, 57%. Eighteen of 70 patients (27%) had pathological 68Ga-PSMA uptake in the prostatic fossa, 11 (14.3%) in the pelvic nodes, and five (4.3%) in both the fossa and pelvic lymph nodes. Finally, there was uptake outside the pelvis with or without a lesion in the fossa or pelvic lymph nodes in four cases (8.6%). As a result of the 68Ga-PSMA findings there was a major management change in 20 (28.6%) patients.

Conclusions
68Ga-PSMA appears to be useful for re-staging of PCa in patients with rising PSA levels who are being considered for salvage RT even at PSA levels <0.5 ng/mL. These results underline the need for further prospective trials to evaluate the changes in RT volume or management attributable to 68Ga-PSMA findings.

Keywords
68Ga-PSMA, PET/CT, prostate cancer, radical prostatectomy, biochemical progression, salvage radiation treatment

Introduction
Radical prostatectomy (RP) is the most widely used treatment for patients with localized prostate cancer (PCa) [1]. After RP, patients are monitored through serial PSA measurements. A persistent or rising PSA level after RP suggests recurrent PCa, which is experienced by 20–30% of patients after RP [2]. Conventional imaging such as TRUS, MRI, CT, positron emission tomography (PET), bone scan and 18F-Fluoromethylcholine PET/CT, are neither sensitive nor
specific enough to detect PCs at an early enough stage where salvage radiation therapy (RT) might still be curative [3–5].

Salvage RT to the prostatic fossa is the only potentially curative treatment option for patients with biochemical recurrence (BCR) after RP [6]. In the salvage setting, a dose of at least 64–68 Gy to the prostatic fossa at the lowest possible PSA level (preferably <0.5 ng/mL) is recommended [6–9]. Overall, the 6-year progression-free survival rate in patients undergoing salvage RT is 32%, varying from 48% to 18% in those with a pre-RT PSA level of <0.5 ng/mL and >1.5 ng/mL, respectively [10]. This indicates that, on the one hand, patients with low-volume recurrent PCs benefit the most from salvage RT and, on the other, that there is a substantial number of patients who do not have a durable response after salvage RT [11]. Currently, neither a rising PSA level nor its combination with other adverse pathological features give specific information concerning disease location (i.e. local vs regional vs distant) [12,13]. Because salvage RT is only clinically useful in patients with local disease (disease confined to the prostatic fossa), patients with tumour spread beyond the prostatic fossa should ideally be excluded when selecting patients for prostatic fossa salvage RT. Alternatively, if regional disease is detected (in the absence of distant disease), then the salvage RT volume might be enlarged to include the pelvic nodes in addition to or instead of the prostatic fossa.

Recent data on the novel PET tracer agent Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)](PSMA) have been shown to have promising sensitivity and specificity for the detection of PCs in patients with early BCR [14–16]. This new PET tracer relies on the overexpression of prostate-specific membrane antigen (PSMA), a transmembrane folate hydrolase, on the surface of PCs cells. This overexpression has been demonstrated both locally and in regional or metastatic lesions within lymph nodes, soft tissue and bone [17]; therefore, imaging with radiolabelled 68Ga-PSMA has the potential to detect lymph node or local recurrence and/or to exclude distant metastases. Of particular clinical relevance, this includes patients with PSA values in the range of those that are exhibited by patients optimally selected for salvage RT [16].

68Ga-PSMA PET/CT has recently been introduced into Australian clinical practice. The aim of the present study was to evaluate the influence of 68Ga-PSMA PET/CT on the intent and planning of salvage RT for BCR after RP. This should, in turn, provide clinical guidance for the use of 68Ga-PSMA PET/CT for a rising PSA level after RP, and direct future clinical trials.

Materials and Methods

Between February and July 2015, 68Ga-PSMA PET/CT was undertaken in 300 consecutive patients at the department of diagnostic imaging, St Vincent’s Hospital, Sydney. All patients were consented for inclusion in the Prostate Cancer Imaging database (ProCan-I). The ProCan-I has the aim to prospectively collect clinical and imaging information on patients requiring a PSMA PET scan for their PCs and to determine how the results of imaging influences the clinical management of patients with PCs. The trial was approved by the institutional Human Research and Ethics Committee.

Patient Population

Men who had undergone RP and were diagnosed with BCR (PSA ≥0.05 and <1.0 ng/mL) and were being considered for salvage RT were selected for the present study. No patients had evidence of local/regional recurrence or metastatic disease on conventional clinical evaluation. In all patients, conventional clinical evaluation included a diagnostic contrast-enhanced CT scan abdomen pelvis, reconstructed by standard CT methods, and separately interpreted by the nuclear medicine physicians for the purpose of this study. Patients previously treated with RT or patients on any systemic treatment were excluded. Data on age, previous therapy, time since RP, initial pathology (including T stage and Gleason score), PSA at the time of 68Ga-PSMA-PET/CT and previous imaging were collected at enrolment.

Imaging Protocol

The PSMA was produced on site according to a Good Laboratory Practices-compliant procedure using a TRASIS® automated radiopharmacy cassette with radiopharmacy quality control undertaken using an HPLC method. All PET/CT imaging was undertaken using a Phillips® Ingenuity TOF–PET/64-slice CT scanner. For the PSMA PET/CT, a non-contrast-enhanced CT scan was performed 45 min after tracer injection using the following CT parameters: slice thickness 2 mm, soft-tissue reconstruction kernel, 120 keV and 50 mAs; pitch of 0.828; field of view, 600 mm; and a 512 matrix. Immediately after CT scanning, a whole-body PET scan was acquired for 2 min per bed position. The emission data were corrected for randoms, scatter and decay using a Phillips® Body-dynamic.xml and Body.xml reconstruction protocol (Phillips, Eindhoven, The Netherlands). All images were viewed and reported using a Phillips® Fusion Viewer.

Image Analysis

The 68Ga-PSMA PET/CT images were independently interpreted by two experienced nuclear medicine physicians. Cases of conflicting outcomes were resolved by consensus between the physicians. Data for all 68Ga-PSMA scans were analysed visually and quantitatively. Visual analysis included
a four-point certainty scoring scale (definitely negative, equivocal probably negative, equivocal probably positive, definitely positive), as well as anatomical site and size of lesions. Quantitative analysis was undertaken using an automated maximum standardized uptake value (SUVmax). All equivocal probably positive and definitely positive lesions were assigned to their respective anatomical location (Appendix 1). All positive lymph nodes were measured in the short axis.

Follow-Up and Patient Management

Two experienced radiation oncologists were asked to report on the management plan for each patient before and after their 68Ga-PSMA PET/CT, all patients were being considered for salvage RT to the prostate fossa according to the Faculty of Radiation Oncology Genito-Urinary Group (FROGG) consensus guideline, i.e. a dose of 64–68 Gy with the treatment fields to the prostatic fossa defined in detail by Sidhom et al. [6]. Changes in management that were attributable to the 68Ga-PSMA results were classified as follows: none, moderate (change in delivery dose, site or volume of the salvage RT) or major (change of selected treatment). Histopathological results for correlation were collected when available.

Statistical Analysis

A positive 68Ga-PSMA scan was defined as an equivocal probably positive or definitely positive interpretation. A McNemar test was used to analyse scan positivity at different PSA intervals (0–0.09, 0.1–0.19, 0.2–0.29, 0.3–0.49 and 0.5–0.99 ng/mL). For continuous variables normality of distribution was verified using a Kolmogorov–Smirnov test. Because variables had no normal distribution, non-parametric tests were used. The Mann–Whitney U-test was used to determine the significance of possible associations. Pearson’s correlation and binary logistic regression analyses were used to identify determinants for differences between the patients with a positive scan and those with a negative scan considering pT stage, pLN stage, Gleason score, PSA level at the time of 68Ga-PSMA scan, PSA before surgery and time (months) after RP. 

Results

Patients

A total of 70 patients met the inclusion criteria and were included in the present study. Patient characteristics are shown in Table 1. The median (interquartile range [IQR]) PSA was 0.2 (0.12–0.32) ng/mL at the time of the 68Ga-PSMA PET/CT.

68Ga-PSMA PET/CT Results

Of the 70 patients, 38 (54.3%) had pathological 68Ga-PSMA uptake, and their median (IQR) PSA was 0.21 (0.15–0.32) ng/mL. In the 24 patients reported as having a ‘definitely’ positive lesion, the median PSA was 0.26 ng/mL compared with 0.18 ng/mL among the equivocal probably positive lesions in 14 patients (P = 0.034). The percentages of patients with equivocal probably or definitely positive 68Ga-PSMA per PSA category are shown in Fig. 1. The percentages of patients who were definitely positive, grouped according to PSA level, are as follows: for PSA 0.05–0.09 ng/mL, 8%; for PSA 0.1–0.19 ng/mL, 23%; for PSA 0.2–0.29 ng/mL, 58%; for PSA 0.3–0.49 ng/mL, 36%; and for PSA 0.5–0.99 ng/mL, 57%.

The total number of lesions detected was 53. The actual numbers and median quantitative SUVmax values per PSA category are shown in Table 2. A significant number of patients had more than one lesion identified on 68Ga-PSMA, which increased as PSA level rose. In 25 patients (65.8%) one positive lesion was detected, in 10 patients (26.3%) two positive lesions and in three patients (7.9%) three positive lesions were detected.

While the percentages in Fig. 1 show a high detection rate at very low PSA levels (50% equivocal probably or definitely positive among men with PSA 0.1–0.19 ng/mL), as would be expected, the data also show reduced levels of certainty with lower-volume disease. This was shown both quantitatively on visual assessment (Figs 1 and 2), and with lesion intensity (Table 2). An example of a relatively common observation is shown in Fig. 2: a 68Ga-PSMA PET/CT in a patient with

Table 1 Patient population characteristics.

<table>
<thead>
<tr>
<th>Variable at RP</th>
<th>No. of men</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (IQR) age, years</td>
<td>62 (57–67)</td>
</tr>
<tr>
<td>Median (IQR) PSA, ng/mL</td>
<td>7.3 (5.2–10.1)</td>
</tr>
<tr>
<td>Tumour stage, n (%)</td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>15 (21.4)</td>
</tr>
<tr>
<td>T3a</td>
<td>41 (58.6)</td>
</tr>
<tr>
<td>T3b</td>
<td>14 (20.0)</td>
</tr>
<tr>
<td>Extracapsular extension, n (%)</td>
<td>53 (75.7)</td>
</tr>
<tr>
<td>Semical vesical invasion, n (%)</td>
<td>14 (20.0)</td>
</tr>
<tr>
<td>Positive surgical margins, n (%)</td>
<td>21 (30%)</td>
</tr>
<tr>
<td>Lymph node stage, n (%)</td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>38 (54.3)</td>
</tr>
<tr>
<td>N1</td>
<td>5 (7.1)</td>
</tr>
<tr>
<td>NX</td>
<td>27 (38.6)</td>
</tr>
<tr>
<td>Gleason score, n (%)</td>
<td>46 (65.7)</td>
</tr>
<tr>
<td>Gleason 7</td>
<td>24 (34.3)</td>
</tr>
</tbody>
</table>

Variable at PSMA scan

Table 2

<table>
<thead>
<tr>
<th>Variable at RP</th>
<th>No. of men</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (IQR) age, years</td>
<td>67 (60–71)</td>
</tr>
<tr>
<td>Median (IQR) PSA, ng/mL</td>
<td>0.2 (0.12–0.32)</td>
</tr>
<tr>
<td>Median (IQR) months after RP</td>
<td>38 (14–69)</td>
</tr>
</tbody>
</table>

IQR: interquartile range; PSMA, prostate-specific membrane antigen; RP, radical prostatectomy.
rising PSA level after RP at two points in time, with a negative result at PSA 0.15 ng/mL and a positive result at PSA 0.27 ng/mL. The median lesion intensity (SUVmax) of all positive lesions was 3.5. The median SUVmax among all ‘definitely’ positive lesions was 4.5, and the median SUVmax in all equivocal probably lesions was 3.0 ($P < 0.05$). The median (range) size of a positive lymph node was 5 (3–8) mm (short axis).

Histopathological confirmation was provided in only three patients (7.9%) with positive findings on $^{68}$Ga-PSMA. Each $^{68}$Ga-PSMA–positive lesion was confirmed to be a true-positive.

**Anatomical Locations of $^{68}$Ga-PSMA-Positive Pathological Lesions**

Of the 70 patients, 18 (27%) had pathological $^{68}$Ga-PSMA uptake in the prostatic fossa, 11 (14.3%) showed abnormal uptake in the pelvic lymph nodes, five (4.3%) in the fossa and pelvic lymph nodes, and four (8.6%) had abnormal uptake outside the pelvis with ($n = 2$) or without ($n = 2$) a positive lesion in the prostatic fossa or pelvic nodes. Figure 3 shows the distribution of the 53 $^{68}$Ga-PSMA-detected lesions in these 38 patients. The numbers in this figure represent the percentage of patients with at least one positive lesion in any given region. The target field for pelvic RT is schematically displayed in Fig. 3 by the dotted contour. Of the 53 positive lesions, four lesions (5.3%) were detected in the prostate bed and 21 (37.5%) were detected in the seminal vesicles. Regionally, 24 lesions (48.2%) were identified in the pelvic lymph nodes. Distantly, two para-aortic lymph nodes (3.5%) and two positive bone lesions (5.3%) were detected (distant disease).

**Analysis of Risk Factors**

Multivariate analysis was performed for the association of clinical variables with a pathological uptake on $^{68}$Ga-PSMA; however, no statistically significant association was determined (Table 3). No risk factors could be identified for the presence of positive lymph nodes outside the prostatic fossa (Table 3).

**Management Impact**

Site of disease recurrence had an important impact on management options. There were 28 positive lesions detected in 20 of 70 patients (28.6%) that were located in either regional lymph nodes or bones that would not have been included in a conventional salvage RT field to the prostatic fossa. After imaging and, accounting for the fact that all patients were considered for salvage RT before the scan, there was no impact on management in 50/70 patients (71.4%). These 50 patients were all either $^{68}$Ga-PSMA-negative or -positive in the prostatic fossa alone.

Furthermore, the 18 patients (25.7%) with $^{68}$Ga-PSMA-positive disease within the prostatic fossa (prostate bed or the seminal vesicles) might have been considered as optimum candidates for salvage RT to the prostatic fossa by their treating radiation oncologists. Consideration might also have

<table>
<thead>
<tr>
<th>PSA ng/mL at PSMA</th>
<th>Patients, n</th>
<th>Lesions, n</th>
<th>Equivocal probably positive, n (%)</th>
<th>SUVmax, median</th>
<th>Definitely positive, n (%)</th>
<th>SUVmax, median</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.05–0.09</td>
<td>13</td>
<td>4</td>
<td>3 (75)</td>
<td>3.0</td>
<td>1 (25)</td>
<td>4.5</td>
</tr>
<tr>
<td>0.1–0.19</td>
<td>22</td>
<td>16</td>
<td>12 (75)</td>
<td>3.2</td>
<td>4 (25)</td>
<td>5.0</td>
</tr>
<tr>
<td>0.2–0.29</td>
<td>17</td>
<td>17</td>
<td>6 (35)</td>
<td>2.9</td>
<td>11 (65)</td>
<td>5.0</td>
</tr>
<tr>
<td>0.3–0.49</td>
<td>11</td>
<td>9</td>
<td>5 (56)</td>
<td>3.0</td>
<td>4 (44)</td>
<td>4.1</td>
</tr>
<tr>
<td>0.5–0.99</td>
<td>7</td>
<td>7</td>
<td>2 (29)</td>
<td>3.1</td>
<td>5 (71)</td>
<td>4.9</td>
</tr>
</tbody>
</table>

PSMA, prostate-specific membrane antigen; SUVmax, maximum standardized uptake value.
been given to focused treatment to a higher dose, using the $^{68}$Ga-PSMA fused with the planning CT to allow a simultaneous integrated boost or ‘dose painting’.

There was a major management impact in 20 patients (28.6%) directly attributable to their $^{68}$Ga-PSMA findings. In total, five patients (25%) had management changes which included enlarging the volume of salvage RT to include pelvic nodes and to consider the addition of adjuvant androgen deprivation therapy (ADT). One patient (5%) underwent a surgical salvage lymph node dissection (omitting salvage RT altogether), six patients (30%) were treated with salvage RT to the pelvic lymph nodes alone plus adjuvant ADT (potentially

---

**Table 3** Association clinical parameters with positive $^{68}$Ga-PSMA lesions (outside prostatic fossa).

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR</th>
<th>P</th>
<th>OR</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSA RP</td>
<td>2.84</td>
<td>0.46</td>
<td>0.69</td>
<td>0.79</td>
</tr>
<tr>
<td>PSA PSMA</td>
<td>1.02</td>
<td>0.75</td>
<td>1.08</td>
<td>0.32</td>
</tr>
<tr>
<td>pT stage</td>
<td>2.37</td>
<td>0.16</td>
<td>4.20</td>
<td>0.07</td>
</tr>
<tr>
<td>pL stage</td>
<td>0.76</td>
<td>0.34</td>
<td>0.92</td>
<td>0.80</td>
</tr>
<tr>
<td>Seminal vesicle invasion</td>
<td>0.48</td>
<td>0.45</td>
<td>0.48</td>
<td>0.49</td>
</tr>
<tr>
<td>Surgical margins</td>
<td>2.32</td>
<td>0.17</td>
<td>1.97</td>
<td>0.29</td>
</tr>
<tr>
<td>Gleason score</td>
<td>0.90</td>
<td>0.86</td>
<td>0.95</td>
<td>0.94</td>
</tr>
<tr>
<td>Time after RP</td>
<td>1.01</td>
<td>0.39</td>
<td>1.01</td>
<td>0.12</td>
</tr>
</tbody>
</table>

OR, odds ratio; PSMA, prostate-specific membrane antigen; RP, radical prostatectomy.
sparing the toxicity of salvage RT to the fossa), four patients (20%) were treated with stereotactic RT of a solitary equivocal probably positive pelvic lymph node alone (all patients had negative surgical margins and ≤pT3a disease), three patients (15%) were treated with stereotactic radiotherapy for a lesion outside the pelvis with or without ADT and one patient (5%) underwent salvage RT to the prostatic fossa plus stereotactic radiotherapy for an extrapelvic lesion.

Discussion

The present study confirms results from recently published studies that 68Ga-PSMA PET/CT is a valuable diagnostic tool in the setting of BCR after RP [15,16]. The detection rate of 68Ga-PSMA PET/CT for recurrent PCa increased in parallel with rises in PSA values. In total, 54% of patients, with PSA values in the range of 0.2–0.5 ng/mL, had a definitely positive lesion. Until now, the onset of PSA increase often occurred long before recurrent disease could be localized clinically or by imaging. Nomograms have been established for predicting the likelihood of local recurrence or metastatic disease, resulting in high rates of overtreatment, i.e. localized salvage RT in patients with systemic disease [13]. The results of the present study show that 68Ga-PSMA promises to differentiate local, regional and distant metastatic disease in recurrent PCa in patients with low PSA values, with considerable implications for disease management. Furthermore, in patients with BCR after RP, it showed that a high percentage of disease recurrence appears to be located beyond the prostatic fossa, and thus outside the standard salvage RT field. These findings are consistent with previous series using lymphotropic nanoparticle-enhanced MRI for the assessment of normal and abnormal lymph nodes in patients with PCa [18].

The present study showed that 58% of men with a PSA 0.2–0.29 ng/mL had pathological uptake on their 68Ga-PSMA scan. Normally, this is the PSA level where patients are considered for salvage RT, giving them potential benefit from early salvage treatment [10,19]. Considering both the present and previous findings [16], it is likely that 68Ga-PSMA will replace other imaging techniques for staging of BCR after RP, and may alter the treatment in men currently considered for salvage prostatic fossa radiotherapy. This highlights the main purpose of the present study, i.e. to show the clinical impact of 68Ga-PSMA in contemporary practice. It underlines the need for additional treatment guidelines and well-designed clinical trials to determine the outcomes in terms of BCR, mortality and morbidity of treatment changes directly attributable to 68Ga-PSMA PET/CT.

One of the main concerns in the management of PCa is the impact of a scan that is not yet well evaluated. We reported a major management change in 35% of patients based on 68Ga-PSMA results, in most of the cases without histopathological confirmation. The exact sensitivity and specificity of 68Ga-PSMA, for different SUVmax values, is still to be established, although the specificity and positive predictive value appears to be very high [15,16,20]. Only limited data on 68Ga-PSMA are available, with all larger series based on retrospective designs [20,21]. Nonetheless, the present results are consistent with the larger retrospective studies, reporting on 332 consecutive patients with BCR after RP, and presenting detection rates for 68Ga-PSMA of 92% for PSA values 1–2 ng/mL, 72% for 0.5–1 ng/mL and 53% for PSA values 0.2–0.5 ng/mL [22]. Recently, in a retrospective analysis of the value of 68Ga-PSMA for the preoperative staging of primary PCa, Maurer et al. [23] showed a specificity of 99%, a positive predictive value of 87%, and a sensitivity and negative predictive value of 73% and 97%, respectively, for the detection of lymph node metastases. Budäus et al. [20] presented an overall sensitivity, specificity, positive predictive value and negative predictive value of 33.3%, 100%, 100% and 69.2% in 30 patients using 68Ga-PSMA for the preoperatively identifying lymph node metastases. In the present study, the median size of undetected lymph node metastases was 4.3 mm [20]. In other words, given its high specificity and ability to reliably demonstrate the dominant nodule, 68Ga-PSMA might be used to delineate dominant nodule boost with salvage RT in future; however, because of its poor sensitivity, 68Ga-PSMA PET/CT can underestimate the extent of disease, which might not justify the changes in treatment plans as presented in this study. Further research is therefore warranted.

It is clear that 68Ga-PSMA enables the detection of PCa recurrence that would otherwise remain undetected. These results suggest that, in a significant percentage of patients with rising PSA levels, salvage RT to the prostatic fossa according to the FROGG consensus guideline would lead to geographic miss and subsequent treatment failure. These findings support the relatively high rate of patients in the study by Stephenson et al. [10] that were reported to have failed early despite salvage prostatic fossa radiotherapy; therefore, 68Ga-PSMA will have implications for future research and the role of salvage RT, with potentially higher rates of cure after salvage RT as a result of improved patient selection or by altering the target volume to include the pelvic lymphatics as well as the prostatic fossa. This may, however, lead to an increase in toxicity. Another option might be to use 68Ga-PSMA for detection and treatment planning by fusing the 68Ga-PSMA with the planning CT to allow ‘dose sculpting’, which involves delivering a higher dose to the macroscopic disease. This would allow a more personalized approach, which may also decrease the salvage RT related toxicity.

In 44% of the patients, 68Ga-PSMA was assessed to be negative, despite BCR being determined. This could be attributable to underestimation of disease in the prostate bed, an area that is frequently obscured because of tracer excretion in the bladder. Certainly, studies of multiparametric MRI in
the same patient population show higher levels of disease recurrence in the recto-prostatic fossa and at the vesico-urethral anastomosis than identified in the present study. Furthermore, this could be attributable to underestimation of disease in pelvic lymph nodes, reflected in the poor sensitivity reported by Budău et al. [20]. The use of PET/MRI may help to overcome this potential limited sensitivity for disease recurrence with $^{68}$Ga-PSMA PET/CT. Furthermore, new fluorine (F-18)-labelled compounds, such as $^{18}$F-DCFPyL (2-(3-[[1-carboxy-5-[[6-$^{18}$F]fluoro-pyridine-3-carbonyl]-amino]-pentyl]-ureido)-pentane dic acid), a new PSMA-selective ligand with a high binding affinity for PSMA, might be able to improve the sensitivity [24].

Salvage RT seems to be more effective when delivered at low PSA levels after BCR [8,10]. King et al. [8] presented level 2A evidence for initiating salvage RT at the lowest possible PSA value, with an average 2.6% loss of recurrence-free survival for each incremental 0.1 ng/mL PSA increase at the time of the salvage RT. Consequently, this might interfere with the optimum value of $^{68}$Ga-PSMA PET/CT, with only 17% of patients in the present study presenting with a definitive $^{68}$Ga-PSMA positive lesion. In other words, the additional value of $^{68}$Ga-PSMA PET/CT in combination with ‘late’ salvage RT (PSA >0.2 ng/mL) vs ‘early’ salvage RT (PSA <0.2 ng/mL) has to be determined as well.

The present study has several limitations. Firstly, in almost all patients, largely because of the small size and anatomical location of subcentimetre lymph nodes, histological examination could not be obtained. Secondly, the study includes a small sample size and thereby a relatively low statistical power; however, the study purpose is to generate a hypothesis rather than to define recommendations in this treatment group, and well-designed, prospective studies are clearly required to address the questions raised by these findings. Finally, no data on PSA kinetics were included.

In conclusion, we established the value of $^{68}$Ga-PSMA PET/CT for the detection of PCa recurrence in men with low serum PSA levels considered for salvage RT after RP. The impact of $^{68}$Ga-PSMA findings on patient management are considerable. In our opinion, this underlines the need for further clinical trials that establish the sensitivity and specificity of $^{68}$Ga-PSMA, and assess the outcomes of treatment changes in salvage therapy attributable to $^{68}$Ga-PSMA. Nevertheless, $^{68}$Ga-PSMA PET/CT has the potential to become a promising tool for individualized salvage treatment in patients with recurrent PCa.

**Acknowledgments**

We thank Ms Anne-Maree Haynes, Clinical Data Manager, Australian Prostate Cancer Research Centre NSW. This research was funded by the Australian Department of Health and Ageing for its funding of the Australian Prostate Cancer Research Centre NSW, and the St Vincent’s Prostate Cancer Centre.

**Conflicts of Interest**

None declared.

**References**

16. Morigi J, Stricker PD, van Leeuwen PJ et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. *J Nucl Med* 2015; 56: 1185–90


Maurer TGJW, Souvatzoglou H, Beer M et al. PET imaging with 68Gallium-labelled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA) for staging of biochemical recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2015; (abstract e5023)

Maurer TGJW, Souvatzoglou H, Beer M et al. PET imaging with of prostate-specific membrane antigen (PSMA) for staging of primary prostate cancer with 68Ga-HBED-PSMA. J Clin Oncol 2015; (abstract e16038)


Correspondence: Pim J. van Leeuwen, Level 6, The Kinghorn Cancer Centre, 370 Victoria Street, Darlinghurst, NSW 2010, Australia.

e-mail: p.vanleeuwen@garvan.org.au

Abbreviations: PET, positron emission tomography; BCR, biochemical recurrence; RP, radical prostatectomy; PCa, prostate cancer; RT, radiation therapy; PSMA, prostate-specific membrane antigen; SUVmax, maximum standardized uptake value; FROGG, the Faculty of Radiation Oncology Genito-Urinary Group; ADT, androgen deprivation therapy.

Supporting Information
Additional Supporting Information may be found in the online version of this article:

Appendix 1 68Ga-PSMA Imaging Reporting Form ProCan-I database site codes